SCHEDULE: Janus Henderson Boosts Protara Stake to 10.6%
Beneficial Ownership Report
Janus Henderson Group PLC and its affiliates have reported a 10.6% beneficial ownership stake in Protara Therapeutics, Inc. common stock as of June 30, 2025.
Summary
- Janus Henderson Group PLC, a Jersey-based parent holding company and investment adviser, reported beneficial ownership of 4,102,620 shares of Protara Therapeutics, Inc. common stock.
- This aggregate amount represents 10.6% of Protara Therapeutics' common stock outstanding.
- Janus Henderson Biotech Innovation Master Fund Ltd, a Massachusetts-based investment company and indirect subsidiary of Janus Henderson Group PLC, beneficially owns 3,512,932 shares, representing 9.1% of the class.
- Both entities hold shared voting and shared dispositive power over their respective reported shares.
- The filing is an Amendment No. 3 to a Schedule 13G, indicating an update to previously reported ownership.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a factual disclosure of beneficial ownership, not a performance report or strategic announcement, thus sentiment is neutral.
Future Outlook
NA
Management Comments
- Securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
- Securities were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
NA
Stakeholder Impact
- Shareholders may perceive increased institutional confidence due to the significant stake held by Janus Henderson Group PLC, potentially influencing market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement (reporting period end date). |
| 08/14/2025 | Date the Schedule 13G Amendment No. 3 was filed. |
| 12/09/2022 | Date of the Power of Attorney granted by Janus Henderson Group plc. |
Keywords
Protara Therapeutics, Janus Henderson, beneficial ownership, Schedule 13G, common stock, institutional investment, biotech, investment adviser, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.